CD8A and non-small cell lung carcinoma: For instance, in KRAS and TP53 mutant non-small cell lung cancer (NSCLC), the enzyme autotaxin (ATX) and its metabolite lysophosphatidic acid (LPA) suppress anti-tumor immunity by reducing CD8+ T cell infiltration.